{"id":125802,"date":"2026-07-09T02:17:11","date_gmt":"2026-07-09T02:17:11","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/125802\/"},"modified":"2026-07-09T02:17:11","modified_gmt":"2026-07-09T02:17:11","slug":"novo-nordisk-deploys-multipronged-counteroffensive-as-eli-lilly-gains-ground","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/125802\/","title":{"rendered":"Novo Nordisk Deploys Multipronged Counteroffensive as Eli Lilly Gains Ground"},"content":{"rendered":"<p>Novo Nordisk is fighting back on multiple fronts as its rival Eli Lilly tightens its grip on the weight-loss market. From a restructuring in Asia to a novel implant partnership and fresh drug approvals in Singapore and Britain, the Danish drugmaker is racing to defend its position while seeking new sources of growth.<\/p>\n<p>The competitive pressure is most visible in South Korea, where Novo Nordisk has merged its obesity and diabetes units and reshuffled management to accelerate decision-making. The moves come after Eli Lilly\u2019s Mounjaro generated 323 billion won in first-quarter sales there \u2014 more than three times what Wegovy managed, despite Novo Nordisk having slashed Wegovy\u2019s price by 40% in an attempt to stem market-share losses. In the United States, the situation is even starker: Lilly\u2019s Zepbound now accounts for roughly 60% of the market, with more than 100,000 additional weekly prescriptions compared with Wegovy.<\/p>\n<p>To counter the threat of \u201ctherapy fatigue\u201d \u2014 a key reason patients abandon injectable weight-loss drugs \u2014 Novo Nordisk has struck a partnership with U.S. biotech company Vivani Medical. The deal centers on Vivani\u2019s NanoPortal technology, a tiny implant placed under the skin that releases semaglutide steadily over months. If successful, the implant could free patients from weekly injections, potentially improving adherence and giving Novo Nordisk a differentiating weapon against Lilly\u2019s lineup.<\/p>\n<p style=\"margin: 2em 0; color: #374151; font-size: inherit; line-height: 1.6; font-style: italic;\"><a href=\"https:\/\/www.stockstoday.com\/lp\/analysis\/?trk=ST_Asset_Analysis_Middle_RSS-Feed&amp;isin=DK0062498333&amp;aktienname=Novo+Nordisk&amp;adref=Blog_Ad-Hoc-News%3AEx-Article-ID_188637%3AISIN_DK0062498333%3AAsset_Novo+Nordisk%3ASource_Ad-Hoc-News&amp;source=RSS-Ad-Hoc-News&amp;Language=English\" rel=\"noopener nofollow\" style=\"color: #337ab7 !important; font-weight: bold; text-decoration: underline;\" target=\"_blank\">Should investors sell immediately? Or is it worth buying Novo Nordisk?<\/a><\/p>\n<p>On the regulatory front, the company secured two important wins. In Singapore, Wegovy received an updated local approval incorporating data from the recent STEP-UP study. The results were striking: one-third of patients lost at least 25% of their body weight over 72 weeks, with an average weight reduction of 21%. Crucially, the lost weight was almost exclusively fat, and patients reported a significant reduction in constant hunger. Meanwhile, in Britain, the MHRA approved Wegovy for a new indication \u2014 metabolic dysfunction-associated steatohepatitis (MASH) with moderate to severe fibrosis. The approval is conditional, requiring Novo Nordisk to submit further clinical data from ongoing studies, but it opens a lucrative new market beyond simple weight loss.<\/p>\n<p>Closer to home, Novo Nordisk is expanding its digital health offering. In Germany, it has launched a new care program for type 2 diabetes patients in collaboration with Smartpatient, a digital health provider. The initiative aims to provide continuous monitoring between doctor visits, adapting a support model already used in obesity care to diabetes management.<\/p>\n<p>The flurry of pipeline advances and strategic moves has calmed investors. Novo Nordisk\u2019s shares have surged roughly 17% to 21% over the past month, trading around \u20ac43. The stock has reclaimed both its 50-day moving average at \u20ac39.20 and its 200-day average, signaling renewed bullish momentum. The relative strength index sits in the low-to-mid 60s \u2014 comfortably in neutral-bullish territory but not yet overbought. Still, the year-to-date performance remains marginally negative, a reminder that the competitive assault from Eli Lilly has not been fully shrugged off. With quarterly results approaching, the next few weeks will test whether this rally has legs.<\/p>\n<p align=\"right\" style=\"font-size:10px;margin:0;\">Ad<\/p>\n<p style=\"margin-bottom: 1em;\">Novo Nordisk Stock: New Analysis &#8211; 9 July<\/p>\n<p style=\"margin-bottom: 1em;\">Fresh Novo Nordisk information released. What&#8217;s the impact for investors? Our latest independent report examines recent figures and market trends.<\/p>\n<p style=\"margin-bottom: 1em;\"><a href=\"https:\/\/www.stockstoday.com\/lp\/analysis\/?trk=ST_Asset_Analysis_Bottom_RSS-Feed&amp;isin=DK0062498333&amp;aktienname=Novo+Nordisk&amp;adref=Blog_Ad-Hoc-News%3AEx-Article-ID_188637%3AISIN_DK0062498333%3AAsset_Novo+Nordisk%3ASource_Ad-Hoc-News&amp;source=RSS-Ad-Hoc-News&amp;Language=English\" rel=\"noopener nofollow\" style=\"color: #337ab7 !important; font-weight: bold; text-decoration: underline;\" target=\"_blank\">Read our updated Novo Nordisk analysis&#8230;<\/a><\/p>\n<p style=\"margin-top:20px;margin-bottom:20px;\">&#13;<br \/>\n\t\t\tDisclaimer zu unseren Artikeln: Keine Anlageberatung, keine Kauf  oder Verkaufsempfehlung. Angaben zu Kursen, Unternehmen und M\u00e4rkten ohne Gew\u00e4hr; \u00c4nderungen jederzeit m\u00f6glich. B\u00f6rsengesch\u00e4fte k\u00f6nnen zu hohen Verlusten f\u00fchren. Unsere Beitr\u00e4ge werden ganz oder teilweise automatisiert mit Unterst\u00fctzung von AI erstellt und gepr\u00fcft.&#13;\n\t\t<\/p>\n","protected":false},"excerpt":{"rendered":"Novo Nordisk is fighting back on multiple fronts as its rival Eli Lilly tightens its grip on the&hellip;\n","protected":false},"author":2,"featured_media":125803,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[2003,61516,61514,20639,12332,20638,20640,61515,5691,3845,272],"class_list":["post-125802","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-asia","tag-counteroffensive","tag-deploys","tag-eli","tag-gains","tag-ground","tag-lilly","tag-multipronged","tag-nordisk","tag-novo","tag-novo-nordisk"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116887620584724622","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/125802","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=125802"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/125802\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/125803"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=125802"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=125802"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=125802"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}